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Apo2 ligand (Apo2L, also known as TRAIL) is a member of the tumour necrosis factor (TNF) family of cytokines that selectively
induces the death of cancer cells, but not of normal cells. We observed that recombinant Apo2L/TRAIL was proapoptotic in early-
passage BTK-143 osteogenic sarcoma cells, inducing 80% cell death during a 24h treatment period. Apo2L/TRAIL-induced apoptosis
was blocked by caspase inhibition. With increasing passage in culture, BTK-143 cells became progressively resistant to the apoptotic
effects of Apo2L/TRAIL. RNA and flow cytometric analysis demonstrated that resistance to Apo2L/TRAIL was paralleled by
progressive acquisition of the decoy receptor, DcR2. Blocking of DcR2 function with a specific anti-DcR2 antibody restored sensitivity
to Apo2L/TRAIL in a dose-dependent manner. Importantly, treatment of resistant cells with the chemotherapeutic agents
doxorubicin, cisplatin and etoposide reversed the resistance to Apo2L/TRAIL, which was associated with drug-induced upregulation
of mRNA encoding the death receptors DR4 and DR5. BTK-143 cells thus represent a useful model system to investigate both the
mechanisms of acquisition of resistance of tumour cells to Apo2L/TRAIL and the use of conventional drugs and novel agents to
overcome resistance to Apo2L/TRAIL.
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Osteosarcoma is the most common primary malignancy of the
skeleton. The first choice of treatment for osteosarcoma is
preoperative chemotherapy (Seki et al, 2000). The agents
doxorubicin (DOX), cisplatin (CDDP) and etoposide (ETP), and
others such as cyclophosphamide, methotrexate and vincristine,
are commonly used in combination therapy to target osteosarcoma
(Bramwell, 2000; Seki et al, 2000). However, the use of
chemotherapy is often associated with the frequent acquisition of
drug-resistant phenotypes and the occurrence of ‘second malig-
nancies’. In addition, the associated cytotoxic side effects on
normal tissues and organs represent a serious limitation to the use
of these agents. Importantly, osteosarcomas are often resistant to
the induction of apoptosis by anticancer agents (Seki et al, 2000),
so that there is a pressing need to develop new and alternative
approaches to the current chemical treatment of this tumour type.
Apo2L/TRAIL is a new member of the tumour necrosis factor
(TNF)-cytokine family that induces cell death in a wide variety of
tumour cell lines, but does not seem to be cytotoxic to many
normal cell types in vitro or in vivo (Ashkenazi et al, 1999;
Walczak et al, 1999; Atkins et al, 2002; Evdokiou et al, 2002).
Apo2L/TRAIL is a type II transmembrane protein that induces
apoptosis through interactions with its death domain-containing
receptors, DR4/TRAIL-R1 and DR5/TRAIL-R2 (Pan et al, 1997a,b;
Sheridan et al, 1997; Walczak et al, 1997). Ligand-dependent
activation of DR4 and DR5 involves receptor multimerisation, with
subsequent recruitment of the intracellular death adaptor mole-
cule, Fas-associated death domain protein (FADD), that engages
the initiator protease caspase-8 (Newton et al, 2001). Fas-
associated death domain protein triggers caspase-8 autoactivation
and subsequently leads to activation of downstream effector
caspases, including caspase-3 and caspase-7, resulting in the
cleavage of cellular substrates and ultimately cell death by
apoptosis (Nagata, 1997; Ashkenazi and Dixit, 1998). Death
receptor activity can be antagonised by the so-called ‘decoy’
receptors for Apo2L/TRAIL, of which there are to date three
known in the human: DcR1/TRAIL-R3/TRID (Degli-Esposti et al,
1997a,b), DcR2/TRAIL-R4/TRUNDD (Marsters et al, 1997; Pan
et al, 1998; Degli-Esposti, 1999) and osteoprotegerin (OPG) (Emery
et al, 1998). DcR1 and DcR2 lack functional death domains and
cannot mediate apoptosis. Osteoprotegerin is a widely expressed
soluble member of the TNF receptor family that is capable of
binding to Apo2L/TRAIL and can block Apo2L/TRAIL-induced
apoptosis (Emery et al, 1998), although its role in doing so has not
been extensively explored.
Received 29 November 2002; revised 7 April 2003; accepted 13 April
2003
*Correspondence: Dr A Evdokiou;
E-mail: andreas.evdokiou@adelaide.edu.au
British Journal of Cancer (2003) 89, 206–214
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sThe relative levels of expression of death and decoy receptors
suggests a possible mechanism, by which cells are rendered
resistant to Apo2L/TRAIL, although the pattern of expression of
Apo2L/TRAIL receptors does not necessarily correlate with
resistance or sensitivity to Apo2L/TRAIL-mediated apoptosis
(Degli-Esposti, 1999; Keane et al, 1999). Recent findings, which
demonstrate that the death and decoy receptors for Apo2L/TRAIL
have different subcellular locations and undergo redistribution
within the cell following treatment with Apo2L/TRAIL (Zhang et al,
2000a,b), highlight other levels of complexity that determine
Apo2L/TRAIL sensitivity. These, and other observations suggest
that, in addition to Apo2L/TRAIL receptor expression and
distribution, the cytotoxic effects of Apo2L/TRAIL are likely to
be mediated by events involving the complex interplay between
proapoptotic and prosurvival pathways (Roy and Nicholson,
2000).
Irrespective of the mechanisms that determine sensitivity or
resistance, animal studies indicate that Apo2L/TRAIL has great
therapeutic potential for many cancer types (Ashkenazi et al,
1999). Apo2L/TRAIL was demonstrated safe and nonimmunogenic
(Ashkenazi et al, 1999; Walczak et al, 1999), was active alone in
some cancer types (Ashkenazi et al, 1999) and exhibited
synergistic activity with chemotherapeutic agents, causing marked
regression or complete remission of tumours (Ashkenazi et al,
1999; Walczak et al, 1999). However, some tumour types are
resistant to Apo2L/TRAIL-induced apoptosis (Bin et al, 2002),
while it has been reported that melanoma cells are frequently
resistant at the time of surgical excision, but regain sensitivity in
cell culture (Nguyen et al, 2001). It is therefore important to
develop an understanding of the factors that lead to sensitivity or
resistance of tumour cells to Apo2L/TRAIL.
Using a panel of human osteosarcoma cell lines, we recently
observed resistance of this type of tumour cell to Apo2L/TRAIL,
which could be overcome by cotreatment with chemotherapeutic
agents (Evdokiou et al, 2002). However, we observed initially that
recombinant Apo2L/TRAIL was proapoptotic in one cell line, the
BTK-143 osteosarcoma cell line. The present study found that with
repeated passage in culture, BTK-143 cells became progressively
resistant to the apoptotic effects of Apo2L/TRAIL. Further analysis
revealed that there was a significant increase in the expression of
DcR2 with repeated passage, which paralleled with a loss of
sensitivity to Apo2L/TRAIL, and suggested a role for DcR2 in
determining resistance to Apo2L/TRAIL-induced apoptosis. Im-
portantly, treatment of the late passage resistant cells with DOX,
CDDP or ETP reversed the resistance to Apo2L/TRAIL and
sensitised late passage cells to Apo2L/TRAIL-induced apoptosis.
These cells therefore represent a useful model system to investigate
the mechanisms of acquisition of resistance of tumour cells to
Apo2L/TRAIL and those by which resistance may be overcome.
MATERIALS AND METHODS
Cells and reagents
The BTK-143 osteogenic sarcoma cell line was obtained from the
American Type Culture Collection (ATCC, Rockville, MD, USA)
and cultured in Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with glutamine (2mM), penicillin (100IUml
 1),
streptomycin (100mgml
 1), gentamicin (160 mgml
 1) and 10%
foetal bovine serum (Biosciences, Sydney, Australia). Cultures
were grown in a humidified atmosphere containing 5% CO2. The
cells were passaged every 3–4 days, after reaching 80% confluency,
into T 75cm
2 tissue culture flasks (Corning, Costar Corp.,
Cambridge, MA, USA). Nontagged homotrimeric Apo2L/TRAIL
was generously provided by Genentech, Inc. (South San Francisco,
CA, USA). Doxorubicin, CDDP, and ETP were obtained from
Pharmacia & Upjohn (Kalamazoo, MI, USA). The tetrapeptide
caspase inhibitors ZVAD-fmk and ZDEVD-fmk were purchased
from Calbiochem (Alexandria, NSW, Australia).
Measurement of cell number
To determine effects on cell number, 2.5 10
4 cells per well were
seeded in 48-well microtitre plates and allowed to adhere to the
plate overnight. Cells were then treated for 24h with 100ngml
 1 of
soluble recombinant Apo2L/TRAIL. Cell number was determined
by staining the cells with crystal violet and measuring OD570nm of
cell lysates. To assess the effects of chemotherapeutic agents on
Apo2L/TRAIL-mediated effects on cell number, cells were plated in
48-well plates and allowed to adhere for 24–48h. Doxorubicin,
CDDP or ETP were added to the wells at the indicated
concentrations either alone, or in combination with 100ngml
 1
of Apo2L/TRAIL, and incubated for 24h. Cell number was again
determined by staining the cells with crystal violet. All cell number
experiments were performed in triplicate or quadruplicate and
experiments were repeated at least three times. Results of
representative experiments are given as the mean 7s.d.
Reverse transcription–polymerase chain reaction analysis
RNA was extracted from cells using the Trizol Reagent (Invitrogen,
Groningen, Netherlands), as recommended by the supplier. First-
strand complementary DNA (cDNA) was synthesised from 2.0mg
of total RNA in a final volume of 20ml using SuperScript II (Life
Invitrogen, BV CH, Groningen, the Netherlands) and random
primers (Bresagen Inc., Adelaide, South Australia). cDNA (1.0ml
out of 20ml) was then amplified by polymerase chain reaction
(PCR) using specific primers corresponding to mRNA encoding
human gene products as outlined in Table 1. The 20ml
amplification mixture contained 1U of AmpliTaq Gold DNA
polymerase (Perkin Elmer, Norwalk, CT, USA), 100ng each of the
50 and 30 primers, 0.2mM dNTPs (Pharmacia Biotech, Uppsala,
Sweden), 1.5mM MgCl2,2 ml1 0   reaction buffer and sterile
DEPC-H2O. Polymerase chain reaction was performed for 23 cycles
for GAPDH and 30–35 cycles for other primer pairs, such that all
products could be assayed in the exponential phase of the
amplification curve, in a thermal cycler (Corbett Research,
Melbourne, Victoria, Australia). After an initial step at 951C for
9min to activate the polymerase, each cycle consisted of 1min of
denaturation at 941C, 1min of annealing at the temperatures
indicated in Table 1, and 1min of extension at 721C. This was
followed by an additional extension step at 721C for 1min. Primer
sequences and predicted PCR product sizes are shown in Table 1.
Amplification products were resolved by electrophoresis on a 2%
wv
 1 agarose gel and poststained with SYBR-1 Gold (Molecular
Probes, Eugene, OR, USA). The relative amounts of the PCR
products were determined by quantifying the intensity of bands
using a FluorImager and ImageQuant software (Molecular
Dynamics, Sunnyvale, CA, USA). Amplified products are repre-
sented as a ratio of the respective PCR product/GAPDH PCR
product. To show that there were no false-positive results, PCR
reactions were carried out using nonreverse transcribed RNA, and
on reaction mixtures to which no RNA was added.
Measurement of DEVD-caspase like activity
DEVD-caspase-3 like activity was assayed by cleavage of zDEVD-
AFC (z-asp-glu-val-asp-7-amino-4-trifluoro-methyl-coumarin), a
fluorogenic substrate based on the peptide sequence at the
caspase-3 cleavage site of poly (ADP-ribose) polymerase (Medina
et al, 1997). Cells (2.5 10
4) grown in 48-well plates were treated as
indicated, washed once with HBSS and resuspended in 200mlo f
NP-40 lysis buffer containing 5mM Tris-HCl, 5mM EDTA and 0.5%
NP-40, pH 7.5. After 15min in lysis buffer at 41C, insoluble
material was pelleted at 15000g and an aliquot of the lysate was
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stested for protease activity. To each assay tube containing 8mM of
substrate in 1ml of protease buffer (50mM HEPES, 10% sucrose,
10mM DTT, 0.1% CHAPS, pH 7.4), was added to 20ml of cell lysate.
Reactions were allowed to proceed for 4h at room temperature in
total darkness, whereupon fluorescence was quantified (Exc 400,
Emis 505) in a Perkin-Elmer LS50 spectrofluorimeter. Optimal
amounts of added lysate and duration of assay were taken from
linear portions of curves as determined in preliminary experi-
ments. One unit of caspase activity was taken as one fluorescence
unit (at slit widths of 12.5nm) per 4h incubation with substrate.
The tetrapeptide caspase inhibitors ZVAD-fmk, and ZDEVD-
fmk were resuspended in DMSO (Sigma-Aldrich, Castle Hill, NSW,
Australia) and were added to cells at the indicated concentrations
30min before treatment with Apo2L/TRAIL. Control cells were
incubated with the equivalent concentration of DMSO.
40,6-diamidine-20-phenylindole dihydrochloride staining of
nuclei
Cells were seeded on plastic chamber slides and treated as
indicated. After two washes with phosphate-buffered saline (PBS),
cells were fixed in an ethanol/acetic acid solution (six parts ethanol
: one part acetic acid) for 10min, washed again with PBS, and
allowed to air-dry overnight. The chamber slides were then
incubated with 0.8mgml
 1 of 40,6-diamidine-20–phenylindole
dihydrochloride (DAPI), (Roche Diagnostics, Castle Hill, NSW,
Australia) in PBS for 2-5min in the dark and at room temperature.
After several washes in PBS, the coverslips were mounted with
n-propyl gallate (antifade, Sigma Chemical Company, St Louis,
MO, USA). 40,6-diamidine-20-phenylindole dihydrochloride stain-
ing was visualised by fluorescence microscopy.
Flow cytometric analysis
For flow cytometric analysis, cells were seeded into fresh culture
flasks 1 day prior to the assay, rinsed twice with PBS and detached
using 2mM EDTA in PBS at 371C for 5min. All subsequent
incubation steps were performed on ice and centrifugation steps
were performed at 41C. Cells were washed twice in PBS by
centrifugation at 200g for 5min, resuspended at 2 10
6 cellml
 1
in blocking buffer (10% BSA/PBS þ 0.1% azide) and 50ml aliquots
of the cell suspensions were added to polypropylene FACS tubes.
To each of these was added 50ml of monoclonal antibody solution
(Mab) specific for human TRAIL receptors TR1, TR2, TR3, TR4
(Zhang et al, 2000a,b) (supplied by Immunex Corp., Seattle, WA,
USA) or isotype-matched nonbinding control Mabs (provided by
Dr Leonie Ashman, University of Newcastle, NSW, Australia), each
diluted to 10mgml
 1 in blocking buffer. After incubation for
45min, the cells were washed twice in wash buffer by centrifuga-
tion at 300g. To the resuspended cell pellets was added 50mlo f
FITC-labelled F(ab0)2 sheep anti-mouse Ig or goat anti-mouse IgG-
PE (Southern Biotechnology, Birmingham, AL, USA), both diluted
1:50 in blocking buffer. The cells were incubated for a further
45min in the dark, washed twice as above, then resuspended and
fixed in 0.5ml of cold 1%wv
 1 paraformaldehyde for analysis by
flow cytometry.
In situ immunofluorescence
Cells were seeded into 8-chamber slides (Nunc, Inc., Naperville, IL,
USA) at 1 10
4 cells per well, and cultured for 24h. In situ
immunofluorescence was performed at room temperature. Cells
were rinsed once in PBS, fixed in 2% paraformaldehyde in PBS for
5min, and permeabilised with 0.1% saponin in PBS containing
10% heat-inactivated pooled normal human serum (permeabilisa-
tion buffer), for 10min. The cells were then washed thrice with PBS
containing 0.1% bovine serum albumin (BSA) and 0.1% NaN3
(wash buffer), and blocked in 5% normal goat serum (NGS)
containing 0.1%wv
 1 NaN3 (blocking buffer) for 60min. The
blocking buffer was removed and monoclonal antibodies (Mab)
specific for human TRAIL receptors TR1, TR2, TR3, TR4 (as
above), OPG (Mab 8051 or isotype-matched nonbinding control
Mabs (as above), each diluted to 10mgml
 1 in blocking buffer as
above, were added for 60min. The slides were washed thrice in PBS
containing 0.05% (vv
 1) Triton X-100. To reveal primary antibody
reactivity, cells were incubated for a further 60min in the dark,
with a 1:30 dilution in PBS of FITC-conjugated goat anti-mouse
F(ab0)2. The cells were washed thrice as above, then resuspended
and fixed in 0.2ml of cold 1%wv
 1 paraformaldehyde for analysis.
The labelled samples were mounted in Univert mountant and
examined using an Olympus Bx 51 fluorescence microscope and
imaged using a Photometrics Coolsnap Fx digital camera (Roper
Scientific, NJ, USA).
Inhibition of function of DcR2
Cells were seeded at 2.5 10
4 cells per well in 48-well microtitre
plates and allowed to adhere overnight. The cells were then
cultured in DMEM (as above) with increasing concentrations of
anti-DcR2 antibody or an isotype matched negative control
antibody (as above), of up to 100mgml
 1 for a period of 24h.
Culture media were then removed and the cells treated for a
following 24h with 100ngml
 1 of recombinant soluble Apo2L/
TRAIL.
Table 1 PCR primers and conditions for the specific amplification by RT–PCR of human mRNA species
Target gene Primer sequences sense (S), antisense (AS)
Annealing
temperature (1C)
Product
size (kb)
DR4 S 50-TGCTGCAGCTCGTACCTAGCTC-30 66 646
AS 50-TTGCTGCTCAGAGACGAAAGTGG-30
DR5 S 50-CTGCAACTGTGACTCCTATG-3’ 66 424
AS 5’-GTCTGCTCTGATCACCCAAC-30
DcR1 S 50-TCCTAGCTTACTCTGCCACCACT-30 66 700
AS 50-CACAATTAGAACTATGATCCCTACG-30
DcR2 S 50-TTCTCATGGGACTTTGGGGACAA-30 66 855
AS 50-CTGTTACTCAGGGTCTCGTTGC-30
OPG S 50-TGCTGTTCCTACAAAGTTTAC-30 62 435
AS 50-CTTTGAGTGCTTTAGTGCGTG-30
FLIP S 50-AATTCAAGGCTCAGAAGCGA-30 62 229
AS 50-GGCAGAAACTCTGCTGTTCC-30
GAPDH S 50-CATGGAGAAGGCTGGGGCTC-30 62 414
AS 50-CACTGACACGTTGGCAGTGG-30
S¼sense primers; AS¼antisense primers. Annealing temperatures were determined empirically using AmpliTaq Gold
(Perkin Elmer) in a gradient thermal cycler (Corbett Research).
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sCell numbers were determined by staining the cells with crystal
violet and measuring OD570nm of cell lysates, as we have described
previously (Evdokiou et al, 2002). In some experiments, relative
cell numbers were also ascertained by staining with WST-1 (Roche
Diagnostics, Mannheim, Germany), which gave identical results to
those obtained with crystal violet (data not shown). All cell
proliferation experiments were performed in triplicate and
experiments were repeated at least three times. Results of
representative experiments are given as the mean 7s.d.
RESULTS
Sensitivity of BTK-143 osteosarcoma cells to recombinant
soluble Apo2L/TRAIL
Treatment of BTK-143 cells with recombinant Apo2L/TRAIL, at a
concentration of 100ngml
 1 for 24h, resulted in a considerable
reduction in cell number, with 80% cell death compared with
untreated control cells (Figure 1A). Morphological changes
characteristic of apoptosis, including chromatin condensation,
nuclear fragmentation and the formation of dense rounded
apoptotic bodies, were evident in a high percentage of the
Apo2L/TRAIL-treated cells following DAPI staining (Figure 1B).
The onset of apoptosis following treatment with Apo2L/TRAIL was
concomitant with a seven-fold increase in the level of caspase-3-
like activity (Figure 1C). The pan-caspase inhibitor, zVAD-fmk,
and the caspase-3-specific inhibitor, zDEVD-fmk completely
prevented the Apo2L/TRAIL-induced apoptosis confirming the
role of caspase activation in Apo2L/TRAIL-mediated apoptosis of
BTK-143 cells (Figure 1D).
With repeated passage in culture, we found that BTK-143 cells
became progressively resistant to the apoptotic effects of Apo2L/
TRAIL. For example, at passage 2, treatment of these cells for 24h
resulted in 80% cell deaths (Figure 2A). By passage 5, only 60% of
the cells were responsive and at passage 10 only 20% of the cells
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Figure 1 Apo2L/TRAIL-induced apoptosis in BTK-143 cells. (A) BTK-143 osteosarcoma cells (1.5 10
4) were seeded into triplicate wells of a 48-well
plate. Cells were incubated for 24h in the absence (white bar) or presence of 100ngml
 1 of soluble recombinant Apo2L/TRAIL (black bar). Cell number
was assessed by crystal violet staining and the results are given as a percentage of control, untreated cells. Data shown are means of triplicate wells 7s.d. and
are representative of experiments repeated at least three times. (B) DAPI nuclear fluorescence stain, showing changes in the nuclei of Apo2L/TRAIL-treated
BTK-143 cells consistent with induction of apoptosis. Left panel: Control, untreated cells showing homogeneously fluorescent nuclei. Right panel: Cells
treated for 24h with 100ngml
 1 Apo2L/TRAIL; note the presence of apoptotic bodies containing condensed chromatin. (C) Caspase-3-like activity in BTK-
143 cells incubated in the absence (white bar) or treated for 24h with 100ngml
 1 of Apo2L/TRAIL (black bar). Activity was determined in cell lysates using
the caspase-3-specific fluorogenic substrate, zDEVD-AFC, as described in the Methods. Data shown are representative of three independent experiments:
bars, 7s.d. (D) Effect of caspase inhibitors on Apo2L/TRAIL-treated BTK-143 cells. Cells were treated for 24h with 100ngml
 1 of Apo2L/TRAIL alone or
with Apo2L/TRAIL and either the pan-caspase inhibitor zVAD-fmk (50mM) or the caspase-3 specific inhibitor zDEVD-fmk (50mM). Cells were also treated
with each inhibitor alone. Cell viability is expressed as a percentage of control untreated cells. Data are means of triplicate results from a representative
experiment repeated at least three times; bars, 7s.d.
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swere responsive to Apo2L/TRAIL, which remained the case at least
up to passage 19 (Figure 2A). Assessment of caspase-3-like
protease activity demonstrated a gradual decrease in the level of
caspase-3 activation by Apo2L/TRAIL as the passage number
increased (Figure 2B).
Apo2L/TRAIL receptor mRNA expression and
Apo2L/TRAIL sensitivity
To determine whether there were any changes in Apo2L/TRAIL
receptor expression with passage number in BTK-143 cells,
semiquantitative reverse transcriptase–polymerase chain reaction
(RT–PCR) analysis was performed to amplify mRNA correspond-
ing to each of the Apo2L/TRAIL receptors. Preliminary experi-
ments were performed to ensure that the number of PCR cycles
used in each case was within the linear phase of each amplification
curve (data not shown). Reverse transcriptase–polymerase chain
reaction analysis of BTK-143 cells at passage 2, 5, 10 and 19
revealed that the mRNA level of the death receptors, DR4 and DR5,
did not notably change with passage (Figure 3). However, with
increasing passage number, the level of mRNA corresponding to
decoy receptors, DcR1 and DcR2, increased markedly, with the
effect on DcR2 expression being more pronounced (Figure 3). At
passage 2, there was little or no detectable DcR1 mRNA and this
increased to readily detectable levels by passage 10. More
dramatically, the level of DcR2 mRNA progressively increased
from undetectable levels at early passage to high levels at later
passage (Figure 3). It has been suggested that sensitivity to Apo2L/
TRAIL might be explained by downstream components of the
Apo2L/TRAIL apoptotic pathway. We therefore examined whether
there was any change in the steady-state level of FLIP mRNA (a
known inhibitor of the Apo2L/TRAIL apoptotic pathway), between
early-passage (sensitive) and late-passage (resistant) cells. Reverse
transcriptase–polymerase chain reaction analysis demonstrated
that the BTK-143 cells expressed high levels of FLIP mRNA, which
did not significantly change with increasing passage number
(Figure 3).
To assess the expression of Apo2L/TRAIL receptors at the
protein level, we performed flow cytometric analysis on intact cells
using specific antibodies to each of the receptors. Our results
clearly demonstrated that cell surface expression of DcR2
increased with passage, and confirmed the data we obtained with
RT–PCR analysis (Figure 4A). There were no detectable changes in
the cell surface expression of either of the two death receptors,
DR4 and DR5, or the other decoy receptor, DcR1. Immunofluor-
escence labelling with an antibody directed against DcR2 demon-
strated a significantly higher level of DcR2 receptor expression in
the late-passaged cells when compared to early-passaged cells. The
1B5 isotype-matched (IgG1) murine monoclonal antibody was
used as a negative control (Figure 4B). The expression of DcR2 was
predominantly cytoplasmic, with strong expression also at the cell
surface. To assess whether the acquired resistance to Apo2L/
TRAIL was attributable to the gain in DcR2 expression, blocking
antibodies against DcR2 were used in late passage, resistant BTK-
143 cells. Preincubation of late-passage cells in the presence of
increasing concentrations of the anti-DcR2 monoclonal antibody
for a period of 24h restored in a dose-dependent manner their
sensitivity to Apo2L/TRAIL-induced apoptosis (Figure 5), whereas
incubation of the cells with an isotype-matched negative control
monoclonal antibody had no effect (data not shown). Taken
together, these results suggest that the gain of DcR2 expression
confers protection from Apo2L/TRAIL-induced apoptosis in these
cells.
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Figure 2 Repeated passage of BTK-143 cells leads to resistance to
Apo2L/TRAIL-induced apoptosis and loss of caspase activation. Apo2L/
TRAIL-sensitive BTK-143 cells were treated for 24h with 100ngml
 1 of
Apo2L/TRAIL. (A) Cell number, represented as a function of total protein
stained with crystal violet, is shown as a percentage of control untreated
cells for the passage (P) numbers indicated. (B) Caspase-3-like activity in
cell lysates prepared from control or Apo2L/TRAIL-treated cells, as
indicated. Caspase-3-like activity was determined using the caspase-3
specific fluorogenic substrate, zDEVD-AFC, as described in the Materials
and Methods. Results represent caspase activation per 15mg lysate protein.
Data are means of triplicate results from a representative experiment
repeated at least three times; bars, 7s.d.
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Figure 3 Reverse transcriptase–polymerase chain reaction analysis of
Apo2L/TRAIL receptor mRNA expression patterns in BTK-143 osteosar-
coma cell line with increasing passage. Analysis of steady-state Apo2L/
TRAIL receptor mRNA expression in the BTK-143 osteosarcoma cells,
assessed by semiquantitative RT–PCR analysis, as described in the
Materials and methods. Expression of the housekeeping gene, GAPDH,
served to normalise for starting mRNA. The panel shows the pattern of
Apo2L/TRAIL receptor expression with increase in passage (P) number.
Note the strong expression of DcR2 at P19.
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sChemotherapy sensitises resistant BTK-143 cells to
Apo2L/TRAIL/-induced apoptosis
Several reports (Gliniak and Le, 1999; Desjosez et al, 2000; Gibson
et al, 2000; Nagane et al, 2000; Yamanaka et al, 2000; Lacour et al,
2001; Mizutani et al, 2001), including our own (Evdokiou et al,
2002), have demonstrated that chemotherapeutic drugs augment
Apo2L/TRAIL-induced apoptosis of sensitive, and more impor-
tantly Apo2L/TRAIL-resistant, cancer cells. Experiments were
performed to determine whether combinations of Apo2L/TRAIL
with chemotherapeutic agents clinically relevant for the treatment
of osteosarcoma, including DOX, CDDP or ETP, could reverse the
acquired resistance to Apo2L/TRAIL. The concentration of each
agent used in the combined treatment with Apo2L/TRAIL was
determined from dose-response curves, and was based on a
concentration at which no more than 25% cell death was obtained
over a 24h treatment period (data not shown). The concentrations
used in these experiments were as follows: DOX 2.0mM, CDDP
12.5mM and ETP 50mM. Cell viability data (expressed as a
percentage of untreated cells), for late-passage (passage 19) BTK-
143 cells, incubated with drug alone, or in combination with
Apo2L/TRAIL, are shown in Figure 6. While neither Apo2L/TRAIL
alone nor chemotherapeutic agent alone had an appreciable effect
on late-passage BTK-143 cells, each of the chemotherapeutic
agents in combination with Apo2L/TRAIL resulted in a significant
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Figure 4 Cell surface expression of Apo2L/TRAIL receptors detected
by flow cytometric analysis and in situ immunofluorescence staining. (A)
Flow cytometric data of cell surface expression of Apo2L/TRAIL receptors
shows strong expression of DcR2 by late-passage (p15) cells, compared
with early-passage (P2) cells (heavy line). The 1B5 isotype-matched (IgG1)
murine monoclonal antibody was used as a negative control (light line).
These results are from a representative experiment repeated at least three
times. (B) In situ immunofluorescence of DcR2 in early-(P3) and late-
passage (P420) BTK-143 cells. Note the strong expression of DcR2 at the
cell surface and within the cytoplasm of the late-passage cells, compared
with the weak or absent staining of early-passage (P3) cells. The 1B5
isotype-matched (IgG1) murine monoclonal antibody shows only weak
staining that is no different between early- and late-passaged cells.
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Figure 5 Effect of blocking the function of DcR2 using a specific anti-
DcR2 antibody. Cells were incubated with DcR2 antibody alone at
increasing concentrations as indicated (open circles) or with anti-DcR2
antibody followed by incubation with 100ngml
 1 recombinant Apo2L/
TRAIL (closed circles). Blocking of DcR2 resulted in a dose-dependent
resensitisation to Apo2L/TRAIL-induced apoptosis in the late-passage-
resistant BTK-143 cells (closed circles) compared with DcR2 antibody
treatment alone (open circles). Viability is expressed as a percentage of the
viability of untreated control cells. An isotype-matched negative control
antibody titrated in a similar manner with Apo2L/TRAIL had no effect (data
not shown).
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Figure 6 Chemotherapeutic agents DOX, CDDP and ETP sensitised
resistant-late passage BTK-143 osteosarcoma cells to Apo2L/TRAIL-
induced apoptosis. Passage 19 BTK-143 cells were seeded into multiwell
plates, as described for Figure 1, and incubated with Apo2L/TRAIL
(100ngml) alone, with sublethal doses of chemotherapeutic agent (2.0mM
DOX, 12.5mM CDDP and 50mM ETP) alone, or with Apo2L/TRAIL and
drug in combination. Cell viability is shown as a percentage of untreated
cells after 24h treatment with Apo2L/TRAIL alone (white bars), drug alone
(grey bars), or the combination of drug and Apo2L/TRAIL (black bars).
Data points show means of quadruplicate results from a representative
experiment, which was repeated three times; bars, 7s.d.
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sincrease in cell death, representing a reversal of the resistant state
of these cells. Reverse transcriptase–polymerase chain reaction
analysis of cells following these treatments did not show any
change in the expression of either DcR1 or DcR2 mRNA. However,
we found that sensitisation of resistant late passage BTK-143 cells
to Apo2L/TRAIL-induced apoptosis by these agents was accom-
panied by a drug-induced upregulation of both DR4 and DR5
death receptors. Figure 7A shows an increase in the expression of
DR4 and DR5 mRNA upon treatment with ETP over a 24h period.
Similarly, flow cytometric analysis of intact cells, using specific
antibodies directed against each of the receptors, clearly demon-
strated that expression of DR4 and DR5 was significantly increased
following treatment with ETP, whereas expression of DcR1 and
DcR2 remained unchanged (Figure 7B). These results confirm the
data we obtained with RT-PCR analysis. Resensitisation to Apo2L/
TRAIL was also accompanied by an increase in the level of FLIP
mRNA (Figure 7A). These data are reminiscent of our previously
published work showing that anticancer agents, including ETP,
DOX and CDDP, upregulate expression of DR4 and/or DR5 in
other osteosarcoma cell lines that are normally resistant to Apo2L/
TRAIL and can sensitise these cells to the apoptotic effects of the
ligand (Evdokiou et al, 2002). In addition, our recent findings in
normal human osteoblasts, in which proapoptotic and protective
components of the Apo2L/TRAIL machinery appear to be
coregulated in response to drugs such as ETP (Atkins et al,
2002), suggests that it is the balance of expression of these
opposing influences that determines the outcome of exposure to
Apo2L/TRAIL. These results show that resistance to Apo2L/
TRAIL-induced apoptosis in BTK-143 cells can be overcome with
the use of conventional chemotherapeutic agents, and suggest that
this may be due at least partly to increased expression of death
receptors.
DISCUSSION
Osteosarcoma accounts for a high percentage of primary
malignant tumours of bone. Treatment regimens have been
developed in the last decade using cytotoxic chemotherapeutic
drugs, which deliver significantly improved prognoses, particularly
in younger patients. However, the toxicity of conventional
chemotherapy limits its usefulness in older patients. Apo2L/TRAIL
has been shown to specifically promote apoptosis in a wide variety
of cancer cell types, and has hence been the subject of intense
study in recent years.
Apo2L/TRAIL is able to induce apoptosis in a caspase-
dependent manner via the activation of death receptors (DR4
and DR5). The mechanisms of differential sensitivity to Apo2L/
TRAIL of different tumour types, or between tumours of the same
type, are not well understood. However, there appear to be
multiple mechanisms that apply, including increased expression of
the decoy receptors for Apo2L/TRAIL (Griffith et al, 1998; Degli-
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Figure 7 Effect of chemotherapeutic agents on the expression of DR4 and DR5. (A) Analysis of Apo2L/TRAIL receptor mRNA expression in the BTK-
143 osteosarcoma cells, assessed by semiquantitative RT–PCR analysis, as described in the Materials and Methods. Expression of the housekeeping gene,
GAPDH, served to normalise for starting mRNA. Right panel shows the pattern of Apo2L/TRAIL receptor expression for late-passage untreated and ETP-
treated BTK-143 cells. Left panel: Fluorimager-generated images of PCR products for DR4 and DR5 shown in the upper panel were quantitated using
IMAGEQUANT software (Molecular Dynamics, Sunnyvale, CA, USA). (B) Flow cytometric data of cell surface expression of Apo2L/TRAIL receptors shows
increased expression of DR4 and DR5 following treatment with ETP (heavy line) compared with untreated cells (grey line). The 1B5 isotype-matched (IgG1)
murine monoclonal antibody was used as a negative control (light line).
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sEsposti, 1999; Keane et al, 1999; Zhang et al, 2000a,b), the over-
expression of intracellular inhibitory proteins such as FLIP
(Griffith et al, 1998), intracellular inhibitor of apoptosis molecules
(IAPs) (Suliman et al, 2001) and the loss of caspase-8 activity by
gene methylation (Siegmund et al, 2001). Although the inherent
expression of the decoy receptors for Apo2L/TRAIL was thought to
be the main determinant of Apo2L/TRAIL resistance, it is,
however, unlikely to be the sole reason given that we (Evdokiou
et al, 2002), and others (Degli-Esposti, 1999; Lacour et al, 2001),
have not been able to demonstrate a consistent correlation between
Apo2L/TRAIL receptor expression and sensitivity to Apo2L/
TRAIL-induced apoptosis.
It is known that cellular responses to Apo2L/TRAIL depend on a
complex interplay between the death and decoy receptors, and
possibly OPG, as well as the participation of proapoptotic and
prosurvival intracellular molecules such as FADD, FLIP, NFkB and
Akt/PKB (Chaudhary et al, 1997; Nesterov et al, 2001; Ravi et al,
2001). It is possible that in a given tissue type, tumour or cell line,
it is the balance of the numerous proapoptotic and prosurvival
factors that determines the response to Apo2L/TRAIL, and that the
perturbation of this balance by a single component may be enough
to change the magnitude or the nature of the response.
Our data suggest that the gain in function or upregulation of the
decoy receptors, in particular DcR2, may be important in the
acquired loss of sensitivity to Apo2L/TRAIL in the osteosarcoma
cell line BTK-143. DcR2 expression in BTK-143 cells progressively
increased with passage in culture, and this increase correlated with
a loss of sensitivity of these cells to Apo2L/TRAIL. Furthermore,
blocking the function of DcR2 in the resistant cells resensitised
them to Apo2L/TRAIL-induced apoptosis. In light of this result, it
is possible that DcR2 is able to provide intracellular antiapoptotic
signals, possibly through transcriptional regulation of other
antiapoptotic genes, and further experiments will need to be
performed to test this possibility.
The reasons for the loss of sensitivity that occurred with
continued passaging in the present experiments are unclear, as
these cells had presumably been extensively passaged prior to their
acquisition for the study reported here. However, the results
suggest that the culture conditions used for the present experi-
ments induced DcR2 expression and thus selected for a more
resistant phenotype. It is well established that some tumour types,
as well as subpopulations of cells within a tumour type, are
resistant to Apo2L/TRAIL-induced apoptosis (Bin et al, 2002).
Also, it has been reported that melanoma cells are frequently
resistant at the time of surgical excision, but regain sensitivity in
cell culture (Nguyen et al, 2001). A similar effect has been
demonstrated in platelets that have been stored for transfusion,
where there is an early increase in the expression of DcR2, but this
increase in expression is not enough to protect platelets from
lesion, caused by apoptosis and caspase activation of these cells
(Plenchette et al, 2001). It is therefore important to develop an
understanding of the factors that lead to sensitivity or resistance of
tumour cells to Apo2L/TRAIL.
We (Evdokiou et al, 2002), and others (Gliniak and Le, 1999;
Desjosez et al, 2000; Gibson et al, 2000; Nagane et al, 2000;
Yamanaka et al, 2000; Lacour et al, 2001; Mizutani et al, 2001),
have shown that Apo2L/TRAIL can be successfully combined with
currently used chemotherapeutic treatments to sensitise already
resistant cancer cells to Apo2L/TRAIL-induced apoptosis. In the
present experiments, combining sublethal concentrations of the
chemotherapeutic drugs DOX, CDDP and ETP with Apo2L/TRAIL
reversed the loss of sensitivity in BTK-143 cells and restored the
initial apoptotic effect. The resensitisation to the effects of Apo2L/
TRAIL by chemotherapy was associated with drug-induced
upregulation of death receptors DR4 and DR5 at the level of
mRNA and protein. This further supports the hypothesis that
perturbation of the balance between the expression of death and
decoy receptors is important in governing sensitivity to Apo2L/
TRAIL-induced apoptosis. Presumably, exposure to sublethal
concentrations of chemotherapeutic agents such as those described
here, altered the balance of these factors in favour of apoptosis by a
process involving upregulation of death receptors. In contrast, we
recently showed that normal human osteoblasts maintain viability
in response to chemotherapeutic drugs and Apo2L/TRAIL
combinations, by coregulating the expression of several antiapop-
totic factors as the expression of death receptors is induced (Atkins
et al, 2002). The molecular mechanisms by which chemother-
apeutic drugs induce DR4 and DR5 expression are not yet
understood and are under intense investigation by this laboratory.
Many anticancer drugs are known to activate the tumour
suppressor protein p53, which can in turn upregulate expression
of death receptors DR4 and DR5 (Gibson et al, 2000). However, we
and others have previously shown that chemotherapy can also
induce expression of DR4 and/or DR5 in cancer cells that are null
or mutant for p53 suggesting that p53-dependent and -indepen-
dent mechanisms may be involved (Evdokiou et al, 2002). The
BTK-143 osteosarcoma cell line used in this study expresses p53,
but whether this protein is wild type or mutant has not been
ascertained.
In summary, our results indicate that the acquisition of function
or the upregulation of decoy receptors, in particular DcR2, is
important in the loss of sensitivity to Apo2L/TRAIL-induced
apoptosis. However, using low concentrations of currently used
chemotherapeutic agents in combination with Apo2L/TRAIL, the
acquired resistance of these cancer cells was reversed. This implies
that future combination therapeutic regimens involving recombi-
nant Apo2L/TRAIL and standard chemotherapeutic drugs for the
treatment of osteosarcoma and other cancer types, may not only
provide a more effective treatment, but would also require lower
doses of drugs than those currently used. The use of such treatment
regimens has exciting implications for reducing the frequency and
the extent of the morbidity experienced by many cancer patients as
a result of both their disease and of their treatment.
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